Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2013

01-03-2013 | Research Article

Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009

Authors: Almudena Zapatero, José López-Torrecilla, Ismael Herruzo, Felipe A. Calvo, SEOR URONCOR GICOR participating Investigators

Published in: Clinical and Translational Oncology | Issue 3/2013

Login to get access

Abstract

Introduction

Little is known of practice patterns on advanced prostate cancer (PC) in Spain. The study objectives were to investigate practice patterns in the management of PC and to determine the adherence to the 2007 Spanish guidelines for the management of PC.

Materials and methods

An epidemiological, cross-sectional study was undertaken. Study-specific questionnaires were distributed to all centers with radiation oncology (RO) facilities delivering megavoltage radiation therapy (RT) in Spain (n = 108). A questionnaire evaluated diagnostic and treatment approaches to PC in low-risk and high-risk cases. And a 12-item questionnaire was used to assess guidelines adherence.

Results

Responses were obtained from 102 centers (94.0 % response rate). In the high-risk scenario, the majority of clinicians (99.0 %) chose combined modality treatment with RT and androgen deprivation (AD) and 93.0 % recommended long-term AD. External-beam RT (EBRT) doses ranging 72–76 Gy were used in 59.5 % of centers and >76 Gy was employed in 40.5 %. In the low-risk scenario, EBRT was chosen by 59.6 %, brachytherapy by 39.4 %, and active surveillance by 1 %. The consensus was high (score 5 + 4 ≥ 90 %) on 8/12 questions assessing adherence to guidelines, being high specifically on items related to RT technique, RT dose, combination of HT and RT in intermediate/high-risk patients, and prognostic factors.

Conclusions

This is the largest survey to date of Spanish RO departments dealing with PC. The study results therefore likely provide a highly reliable picture of clinical practice in Spain in this century and show how this practice is influenced by clinical evidence from randomized trials and consensus conferences.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cáncer de Próstata. Enfoque Multidisciplinar. URONCOR. In: Torrecilla JL (ed) Grupo URONCOR SEOR. Madrid 2007 Cáncer de Próstata. Enfoque Multidisciplinar. URONCOR. In: Torrecilla JL (ed) Grupo URONCOR SEOR. Madrid 2007
2.
go back to reference Nogueira L, Wang L, Fine SW et al (2010) Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75:472–477PubMedCrossRef Nogueira L, Wang L, Fine SW et al (2010) Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75:472–477PubMedCrossRef
3.
go back to reference Roach M 3rd, Waldman F, Pollack A (2009) Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115(13 Suppl):3112–3120PubMedCrossRef Roach M 3rd, Waldman F, Pollack A (2009) Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115(13 Suppl):3112–3120PubMedCrossRef
4.
go back to reference Vergis R, Corbishley CM, Thomas K et al (2010) Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys 78:35–41PubMedCrossRef Vergis R, Corbishley CM, Thomas K et al (2010) Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys 78:35–41PubMedCrossRef
5.
go back to reference Shelley MD, Kumar S, Wilt T et al (2009) A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 351:9–17CrossRef Shelley MD, Kumar S, Wilt T et al (2009) A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 351:9–17CrossRef
6.
go back to reference Bria E, Cuppone F, Giannarelli D et al (2009) Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 115:3446–3456PubMedCrossRef Bria E, Cuppone F, Giannarelli D et al (2009) Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 115:3446–3456PubMedCrossRef
7.
go back to reference McGowan D, Hunt D, Jones C et al (2010) Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b–T2b adenocarcinoma of the prostate and psa ≤20: initial results of rtog 94–08. Int J Radiat Oncol Biol Phys 77:1CrossRef McGowan D, Hunt D, Jones C et al (2010) Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b–T2b adenocarcinoma of the prostate and psa ≤20: initial results of rtog 94–08. Int J Radiat Oncol Biol Phys 77:1CrossRef
8.
go back to reference Zelefsky MJ, Khalid N, Lee W et al (2010) Results from the Quality Research in Radiation Oncology (QRRO) Survey evaluating adherence to quality measures for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 78(Suppl):s78CrossRef Zelefsky MJ, Khalid N, Lee W et al (2010) Results from the Quality Research in Radiation Oncology (QRRO) Survey evaluating adherence to quality measures for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 78(Suppl):s78CrossRef
9.
go back to reference Ogawa K, Nakamura K, Sasaki T et al (2011) Radical external beam radiotherapy for clinically localized prostate cancer in Japan: changing trends in the patterns of care process survey. Int J Radiat Oncol Biol Phys 81:1310–1318PubMedCrossRef Ogawa K, Nakamura K, Sasaki T et al (2011) Radical external beam radiotherapy for clinically localized prostate cancer in Japan: changing trends in the patterns of care process survey. Int J Radiat Oncol Biol Phys 81:1310–1318PubMedCrossRef
10.
go back to reference Nakamura K, Ogawa K, Sasaki T et al (2009) Patterns of radiation treatment planning for localized prostate cancer in Japan: 2003–05 patterns of care study report. Jpn J Clin Oncol 39:820–824PubMedCrossRef Nakamura K, Ogawa K, Sasaki T et al (2009) Patterns of radiation treatment planning for localized prostate cancer in Japan: 2003–05 patterns of care study report. Jpn J Clin Oncol 39:820–824PubMedCrossRef
11.
go back to reference Vordermark D, Marold D, Wirth S et al (2007) Patterns of care in the radiotherapy of prostate cancer in northern Bavaria 1998–2000. Strahlenther Onkol 183:314–320PubMedCrossRef Vordermark D, Marold D, Wirth S et al (2007) Patterns of care in the radiotherapy of prostate cancer in northern Bavaria 1998–2000. Strahlenther Onkol 183:314–320PubMedCrossRef
12.
go back to reference Zelefsky MJ, Moughan J, Owen J et al (2004) Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59:1053–1061PubMedCrossRef Zelefsky MJ, Moughan J, Owen J et al (2004) Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59:1053–1061PubMedCrossRef
13.
go back to reference Dearnaley DP, Hall E, Lawrence D et al (2005) Phase-III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92:488–498PubMedCrossRef Dearnaley DP, Hall E, Lawrence D et al (2005) Phase-III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92:488–498PubMedCrossRef
14.
go back to reference Van Tol-Geerdink JJ, Stalmeier PF, Pasker-De Jong PC et al (2006) Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 64:5343–5345 Van Tol-Geerdink JJ, Stalmeier PF, Pasker-De Jong PC et al (2006) Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 64:5343–5345
15.
go back to reference Zapatero A, Valcárcel F, Calvo FA et al (2005) Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23:6561–6568PubMedCrossRef Zapatero A, Valcárcel F, Calvo FA et al (2005) Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23:6561–6568PubMedCrossRef
16.
go back to reference López Torrecilla J, Guedea F, Heeren G et al (2006) Patterns of care for brachytherapy in Europe. Results in Spain. Clin Transl Oncol 8:362–368PubMedCrossRef López Torrecilla J, Guedea F, Heeren G et al (2006) Patterns of care for brachytherapy in Europe. Results in Spain. Clin Transl Oncol 8:362–368PubMedCrossRef
17.
go back to reference Lee WR, Moughan J, Owen JB et al (2003) The 1999 patterns of care study of radiotherapy in localized prostate carcinoma. A comprehensive survey of prostate brachytherapy in the United States. Cancer 98:1987–1994PubMedCrossRef Lee WR, Moughan J, Owen JB et al (2003) The 1999 patterns of care study of radiotherapy in localized prostate carcinoma. A comprehensive survey of prostate brachytherapy in the United States. Cancer 98:1987–1994PubMedCrossRef
18.
go back to reference Sartor O, McLeod DG, Halabi S et al (2010) The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 75:623–629PubMedCrossRef Sartor O, McLeod DG, Halabi S et al (2010) The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 75:623–629PubMedCrossRef
19.
go back to reference Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307–314PubMedCrossRef Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307–314PubMedCrossRef
20.
go back to reference Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67:1106–1112PubMedCrossRef Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67:1106–1112PubMedCrossRef
Metadata
Title
Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009
Authors
Almudena Zapatero
José López-Torrecilla
Ismael Herruzo
Felipe A. Calvo
SEOR URONCOR GICOR participating Investigators
Publication date
01-03-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0913-0

Other articles of this Issue 3/2013

Clinical and Translational Oncology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine